// App-Quantinova.ai

TCT-429 : Safety, feasibility and performance of the first 300 everolimus-eluting bioresorbable scaffold PCI in an all-comers population with ischemic heart disease

Researchers

Presenter

  • Arif Al Nooryani

Principal Investigators

  • Wael Elabbassi

  • Marija Markovic

  • amit bhatia

  • Galal Kerfes

  • Loai Abudaqa

  • Anoop Mansoor

  • bassam al baba

  • Nagwa Abdel Rahman

Medical Centers

  • Alas sims hospital, Sharjah, United Arab Emirates

  • Medanta Super Speciality Hospital, Indore, Madhya Pradesh, India

  • Cosmopolitan Hospital, Thiruvananthapuram, Kerala, India

  • Alas sims hospital, Sharjah, United Arab Emirates

  • Al Noor Hospital, Abu Dhabi, United Arab Emirates

  • The Everett Clinic, Everett, WA

  • Alas sims hospital, Sharjah, United Arab Emirates

  • Alas sims hospital, Sharjah, United Arab Emirates

  • Al Noor Hospital, Abu Dhabi, United Arab Emirates

Locations

  • United States

  • India

  • United Arab Emirates

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Acute Coronary Syndromes

  • Coronary Artery Disease

  • Diabetes

  • Dyslipidemia

  • Hypertension

  • Venous thrombosis

  • Angina

Biomarkers

  • N/A

Drug/Treatment

  • Everolimus

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved